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New therapies for human spinal cord injuries are badly needed (Ahuja et al., 2017). It is a 
challenging task because injuries are heterogeneous in terms of spinal location and severity. 
Ideally a therapy will work for survivors with acute injuries or chronic injuries that have 
happened less recently. In this issue of Brain, Nick Jeffery and his team describe a successful 
clinical trial of a drug therapy for chronic spinal cord injury (Hu et al., 2018) which led to an 
improvement in limb co-ordination during walking.  
 
This clinical trial was carried out using dogs that had suffered naturally occurring spinal cord 
injuries; for example, as a consequence of road traffic accidents or herniated intervertebral 
discs, which occur commonly in Dachshunds and other dogs with disproportionally long 
vertebral columns. These injuries vary in terms of spinal level, severity and time since injury; as 
such, these dogs provide an opportunity to evaluate a therapy in a heterogeneous population of 
subjects prior to evaluating a therapy in a cohort of humans with spinal cord injuries that are 
likely to be heterogeneous even after selection for inclusion (Figure 1). These canine injuries 
have good face validity; they result from a variety of accidents rather than from controlled, 
defined injuries induced surgically under anaesthesia (like human injuries and unlike most other 
preclinical studies): accordingly, they are likely to have good predictive validity. 
 
The candidate therapy assessed was chondroitinase ABC (“Chase”) which is a bacterial 
enzyme that removes sugar side chains from extracellular matrix molecules including 
chondroitin sulphate proteoglycans. These are found within the intact and injured nervous 
system and are potent inhibitors of axonal growth. Degradation of chondroitin sulphate sugar 
side chains with Chase has been shown to improve axon growth in vitro and in vivo in many 
publications in many species including mice, rats, cats, squirrel monkeys (Moon et al., 2001; 
Bradbury et al., 2002; Jefferson et al., 2011; Bowes et al., 2012) and now dogs. After spinal 
cord injury, Chase has also been shown to enhance neuroplasticity in different spinal networks 
leading to functional improvements in breathing (Alilain et al., 2011) as well as walking 
(Bradbury et al., 2002) and grasping (Garcia-Alias et al., 2009). The fact that many independent 
laboratories have each found benefits of Chase with few, if any, reports of side effects, is 
encouraging. 
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This clinical trial is of an unusually high methodological standard for work using animals. It is a 
properly controlled, randomized, clinical trial with observers blinded to intervention. The 
treatment was delivered using clinically-feasible percutaneous injections into spinal cord under 
fluoroscopic guidance; control dogs received needle puncture of the skin to maintain blinding of 
observers. Relatively large volumes were injected directly into the spinal cord parenchyma and 
in the future it will be important to fully evaluate the risk factors and safety of this approach. The 
trial was based on prior sample size calculations (with power of ≥80% to detect the effect size of 
interest) and a large number of dogs (60) were randomised into the trial. The primary outcome 
measure was analysed on an Intention-To-Treat basis (i.e., involving all animals that were 
randomized to treatment); to enable this, statistical analyses involved a multilevel linear model 
which can handle missing data. Since the subjects were pet dogs, their tissues were, quite 
understandably, not available for anatomical, molecular and biochemical assessment of 
mechanism of recovery although neurophysiology was used to seek changes in connectivity. 
There were no differences between groups in improvement in bladder compliance. Adverse 
events were minor and there was no evidence for increased limb withdrawal responses in 
response to Von Frey filaments. Although it is stated in the paper that the primary outcome 
measure was pre-specified in a grant application, in the future it will be even better if veterinary 
clinical and preclinical trials of this kind are pre-specified publically in a date-stamped immutable 
repository (e.g., in a Registered Report; https://cos.io/rr/).  
 
The magnitude of the improvements in co-ordination in this paper may be modest if one looks at 
the average difference between the groups but several Chase-treated dogs (3 out of 30, 
reflecting 10% of the treated population) recovered independent ambulation. Moreover, this 
effect size is likely to be a reasonable estimate of the “true” population effect size because this 
is a study involving a reasonably large number of dogs which is of very high methodological 
quality. Furthermore, given that Chase induced recovery in dogs treated many months after 
spinal cord injury (i.e., after the phase of cell death is largely complete), it is encouraging that, 
additionally, Chase can increase recovery after acute spinal cord injury via neuroprotective 
mechanisms (Bartus et al., 2014); accordingly, the magnitude of improvements in larger animals 
might yet be increased if the intervention can be given earlier after injury. 
 
Furthermore, continued efforts to optimise this therapy are being made. To prolong activity of 
the enzyme, the Chase used in this study was buffered in trehalose (which stabilizes proteins 
and helps retain the activity of enzymes) and embedded in lipid microtubes (which enable 
sustained release). Prior work in rodents indicates sustained local delivery for 6 weeks with this 
preparation, which is an advance from previous protocols that involved multiple repeat injections 
(e.g. Bradbury et al., 2002). However, it is possible that even longer-term delivery may be 
necessary to achieve more significant functional improvements, as recent gene therapy studies 
in rodents suggest, where viral vector delivery of Chase enabled prolonged administration over 
many spinal segments (Bartus et al., 2014). Other efforts are focused on generating mutated 
variants of Chase with improved thermal stability and mammalian compatibility, as well as 
pharmacological approaches to mimic the action of Chase, for example by inhibiting 
proteoglycan sulfation. It will be interesting to evaluate the efficacy of these emerging 
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therapeutics, as potentially they may have a faster route to gaining regulatory approval than the 
native Chase enzyme. 
 
Of note however, there are several clinical trials, either active or completed, that have used a 
clinical grade preparation of bacterial Chase (SI-6603, generic name Condoliase) for the 
treatment of patients with lumbar disc herniation involving nerve root compression. A recent 
randomized, double-blind, multicentre Phase III trial successfully met its primary end point with 
significantly greater reductions in worst leg pain within 13 weeks in patients that received 
Condoliase injected into the intervertebral disc compared to patients with control injections; their 
one year follow-up suggests that Condoliase, at least when injected into a disc, is safe and well 
tolerated in this patient group (Chiba et al., 2017). This is promising in the step towards clinical 
translation of Chase for spinal cord injury. Nevertheless, concerns remain over potential 
immunogenicity of this bacterial protein when injected into the central nervous system and de-
immunization of the protein may be required, and/or rigorous pre-clinical testing to prove it is 
non-immunogenic, before regulatory approval is granted for clinical trials involving people with 
spinal cord injuries who are often immunocompromised. 
 
In conclusion, this work shows it is feasible, sensitive and effective to evaluate candidate 
therapies for spinal cord injury in well-powered, blinded, randomized, controlled trials using a 
heterogeneous and relatively large cohort of naturally-injured large animals. These data shows 
that Chase is safe and effective in improving gait in another large species. Together with the 
positive human Phase III data for herniated lumbar discs, the Chase is on! 
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Figure 1 Route to clinical translation of Chase and other therapeutics for spinal cord 
injury. There is a pressing need to advance experimental therapies for spinal cord injury to the 
clinic. However, the clinical translation of novel therapeutics for spinal cord injury is notoriously 
slow. The most direct route is to advance directly from small animal (mainly rodent) pre-clinical 
studies to human trials (depicted by red arrow) and this has been the route for several stem cell 
and pharmacological therapies. However, to date there has been limited clinical success, 
possibly due to the heterogeneity of the clinical population. There is merit in using large animal 
models prior to human trials and current therapies such as anti-NOGO-A antibody treatment 
(ATI-355: NCT00406016) and autologous human Schwann cells (ahSC: NCT01739023) have 
followed this route (depicted by blue arrows). These pre-clinical models can prove valuable for 
dosing, biodistribution and surgical refinement studies (e.g. the porcine spinal cord is similar in 
size to the human spinal cord) and for evaluating efficacy in a species closer to human (e.g. 
primates for studies of skilled hand function). However, these studies can be precluded due to 
prohibitive costs and ethical hurdles. Hu et al. used an alternative route to evaluate a promising 
experimental regenerative therapy (Chase). Based on preclinical basic research findings, 
derived largely from rodent models, they evaluated this therapy in a canine clinical population. 
This is a population of pet dogs who have sustained a spinal cord injury and can be enrolled in 
clinical trials at a veterinary research institution. This type of trial provides an opportunity to 
assess the potential of an experimental therapeutic in a clinical group with heterogenous injuries 
of different severities, sustained at different spinal levels, and whose injuries are considered 
chronic since they were sustained at least 3 months prior to trial recruitment, when any 
spontaneous recovery would have reached a plateau. Thus, this population can serve as a 
model for the majority of patients living with spinal injuries. In a rigorous trial design, they 
demonstrated improvements in forelimb-hindlimb coordination on a treadmill in the treated 
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group and a small percentage of the treated dogs even recovered independent ambulation. 
Although these effects may appear modest, detection of benefit in real-life heterogenous spinal 
injuries, with no observable adverse effects, represents a significant advance. The potential 
pathway from rodent basic research, to canine clinical trials and then human trials is depicted by 
green arrows and represents the possibility of reduced cost and accelerated progression of 
promising experimental therapies such as Chase to Phase I clinical trials in humans. 
 
 
Glossary terms 
• Chase (Chondroitinase ABC): a bacterial enzyme that degrades chondroitin sulphates. 
• Chondroitin sulphate: growth inhibitory glycosaminoglycan sugar side chains that extend 
from a proteoglycan core protein. 
• Neuroplasticity: the ability of axonal projections to sprout and form new synaptic connections 
following injury 
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